Innovation Pharmaceuticals Inc (IPIX)

[cabel]

The following explains our enthusiasm for the Phase 2b results coming soon!

Looking only at the 200mg arm in which there were a total of 27 patients:

18 started with IGA-3 (Moderate)
9 started with IGA-2 (Mild)

After twelve weeks with relatively mild side effects we see that:

Using the PP (Per Protocol):

8 patients ended with IGA-3
4 patients ended with IGA-2

We started with 27 Mod/Mild patients and ended with 12 Mod/Mild patients,.. a reduction of 15 patients (who were now progesssed to IGA 1 or 0,.. almost clear or clear)


Using the ITT (Intent to Treat):

7 patients ended with IGA-3
5 patients ended with IGA-2

For a total of 12 patients that had IGA-2/3 when 27 patients started with IGA-2/3.

We see in both cases plenty to be positive about!


Also in the Phase 2b results coming soon we will have 3 points in our favor:

- We will no longer have the Mild patient group but instead will be using Severe psoriasis patients

- We will be increasing the dosage from 200mg to 300mg and 400mg

- We will be using PASI and not IGA as system of measurement.